234 related articles for article (PubMed ID: 16310929)
1. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.
Bex A; Kerst M; Mallo H; Meinhardt W; Horenblas S; de Gast GC
Eur Urol; 2006 Jan; 49(1):76-81. PubMed ID: 16310929
[TBL] [Abstract][Full Text] [Related]
2. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.
Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC
Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246
[TBL] [Abstract][Full Text] [Related]
3. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ.
Bex A; Horenblas S; Meinhardt W; Verra N; de Gast GC
Eur Urol; 2002 Dec; 42(6):570-4; discussion 575-6. PubMed ID: 12477652
[TBL] [Abstract][Full Text] [Related]
4. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Flanigan RC; Salmon SE; Blumenstein BA; Bearman SI; Roy V; McGrath PC; Caton JR; Munshi N; Crawford ED
N Engl J Med; 2001 Dec; 345(23):1655-9. PubMed ID: 11759643
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report.
Miyake H; Hara I; Sakai I; Harada K; Inoue TA; Eto H; Takechi Y; Fujisawa M
Int J Clin Oncol; 2005 Oct; 10(5):338-41. PubMed ID: 16247661
[TBL] [Abstract][Full Text] [Related]
6. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
[TBL] [Abstract][Full Text] [Related]
7. Interferon-α-based immunotherapy in metastatic renal cell carcinoma patients with the primary tumor in situ.
Shinohara N; Abe T; Sazawa A; Maruyama S; Shindo J; Sato S; Suzuki S; Nonomura K
Jpn J Clin Oncol; 2012 Feb; 42(2):113-9. PubMed ID: 22131341
[TBL] [Abstract][Full Text] [Related]
8. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b.
Mutlu H; Gündüz S; Büyükçelik A; Yıldız O; Uysal M; Tural D; Bozcuk H; Coşkun HŞ
Clin Genitourin Cancer; 2014 Dec; 12(6):447-50. PubMed ID: 25022784
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
Kinouchi T; Meguro N; Maeda O; Saiki S; Kuroda M; Usami M; Kotake T
Int J Urol; 1996 Jan; 3(1 Suppl):S41-3. PubMed ID: 24304021
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
13. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
Mickisch GH; Garin A; van Poppel H; de Prijck L; Sylvester R;
Lancet; 2001 Sep; 358(9286):966-70. PubMed ID: 11583750
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].
Schenck M; Börgermann C; Jäger T; vom Dorp F; Sperling H; Rübben H; Lümmen G
Urologe A; 2007 May; 46(5):528-34. PubMed ID: 17356836
[TBL] [Abstract][Full Text] [Related]
15. Extended continuous oral temozolomide in patients with progressive metastatic renal cell carcinoma not responding to interferon alpha 2b.
Bex A; Kerst J; Mallo H; Van Tinteren H; Horenblas S; De Gast GC
J Chemother; 2005 Dec; 17(6):674-8. PubMed ID: 16433200
[TBL] [Abstract][Full Text] [Related]
16. Metastatic renal cell carcinoma treated with Peg-interferon alfa-2b.
Lyrdal D; Stierner U; Lundstam S
Acta Oncol; 2009; 48(6):901-8. PubMed ID: 19274498
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.
Lancet; 1999 Jan; 353(9146):14-7. PubMed ID: 10023944
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.
Flanigan RC; Mickisch G; Sylvester R; Tangen C; Van Poppel H; Crawford ED
J Urol; 2004 Mar; 171(3):1071-6. PubMed ID: 14767273
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.
Fosså SD; Mickisch GH; De Mulder PH; Horenblas S; van Oosterom AT; van Poppel H; Fey M; Croles JJ; de Prijck L; Van Glabbeke M
Cancer; 2004 Aug; 101(3):533-40. PubMed ID: 15274066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
